Bayer Ag ADR (OP:BAYRY)

12.64 UNCHANGED

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

October 02, 2026

From Bayer

Via Business Wire

Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle

October 01, 2026

From Bayer

Via Business Wire

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

September 29, 2026

From Bayer

Via Business Wire

U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer

September 28, 2026

From Bayer

Via Business Wire

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs

September 17, 2026

From Bayer

Via Business Wire

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

September 17, 2026

From Bayer

Via Business Wire

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

September 10, 2026

From Bayer

Via Business Wire

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

September 09, 2026

From Bayer

Via Business Wire

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION

September 09, 2026

From Bayer

Via Business Wire

Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026

August 30, 2026

From Bayer

Via Business Wire

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

August 20, 2026

From Bayer

Via Business Wire

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

July 28, 2026

From Bayer

Via Business Wire

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

July 23, 2026

From Bayer

Via Business Wire

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

July 17, 2026

From Bayer

Via Business Wire

Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming

July 14, 2026

From Bayer

Via Business Wire

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials

July 07, 2026

From Bayer

Via Business Wire

Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart

July 02, 2026

From Bayer

Via Business Wire

Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon

July 01, 2026

From Bayer

Via Business Wire

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Bayer and Iambic Collaborate to Advance Drug Discovery with AI

June 22, 2026

From Bayer

Via Business Wire

Bayer Completes Acquisition of Perfuse Therapeutics

June 17, 2026

From Bayer

Via Business Wire

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief

June 16, 2026

From Bayer

Via Business Wire

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

June 15, 2026

From Bayer

Via Business Wire

Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business

June 09, 2026

From Bayer

Via Business Wire

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

June 08, 2026

From Bayer

Via Business Wire

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

June 05, 2026

From Bayer

Via Business Wire

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

June 02, 2026

From Bayer

Via Business Wire

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

May 30, 2026

From Bayer

Via Business Wire

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

May 21, 2026

From Bayer

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.